Effects of soy isoflavones on serum lipids and lipoprotein (a) in peritoneal dialysis patients

• Published in: Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2020-07, Vol.30 (8), p.1382-1388
• Main Authors: Yari, Zahra, Tabibi, Hadi, Najafi, Iraj, Hedayati, Mehdi, Movahedian, Mina
• Format: Article
• Language: English
• Subjects: Biomarkers - blood; Cholesterol, HDL - blood; Dietary Supplements - adverse effects; Double-Blind Method; Female; Glycine max - chemistry; HDL-C; Humans; Iran; Isoflavones - administration & dosage; Isoflavones - adverse effects; Isoflavones - isolation & purification; Kidney Diseases - blood; Kidney Diseases - diagnosis; Kidney Diseases - therapy; LDL-C; Lipoprotein (a); Lipoprotein(a) - blood; Male; Middle Aged; Peritoneal dialysis; Peritoneal Dialysis, Continuous Ambulatory - adverse effects; Soy isoflavones; Time Factors; Total cholesterol; Treatment Outcome; Triglycerides
• ISSN: 0939-4753; 1590-3729
• DOI: 10.1016/j.numecd.2020.04.023

Lipid abnormalities are common in peritoneal dialysis (PD) patients and no effective treatment to decrease serum lipoprotein (a) [Lp(a)] in dialysis patients is known so far. Therefore, this research was designed to investigate the effects of soy isoflavone supplement on serum lipids and Lp(a) in PD patients. In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the isoflavone or the placebo group. The patients in the isoflavone group received 100 mg soy isoflavone daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of the 8th week, 7 mL of blood was obtained from each patient and serum triglycerides, total cholesterol, low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and Lp(a) were measured. Serum Lp(a) reduced significantly up to 10% in the isoflavone group at the end of week 8 compared to baseline (P